Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
The group plans to convene experts and stakeholders in Chicago in December to discuss a newly proposed CPT coding framework for AI software services that don’t involve a clinician work component. A major focus will be on how the envisioned system will translate into consistent reimbursement for these rapidly evolving technologies.
Investors in diagnostics have focused their attention on liquid biopsy technologies for early detection of cancer and screening applications, but companies are seizing minimal residual disease (MRD) testing as a near-term opportunity. Strategies for implementation are a work in progress for all stakeholders—payors, patients, providers, and regulators.
The agency has issued final guidance on allowing unauthorized diagnostics in a federally declared emergency. Excerpted from Pathways’ Picks September 24: Breakthrough Bill Optimism, EU Reform Talk, Malaysia Joins MDSAP.